herrera.jpg

 

Professor of Medicine
Director, Section of Hepatology
Education:    
B.S., University of Puerto Rico
                      M.D., University of Puerto Rico
Internship:    Internal Medicine, Fitzsimons Army Medical Center, Denver,
                      Colorado
Residency:    Internal Medicine, Fitzsimons Army Medical Center, Denver,
                      Colorado
Fellowship:   Gastroenterology, Walter Reed Army Medical Center,
                      Washington, D.C.
Board Certifications:  American Board of Internal Medicine, Gastroenterology,
Diplomate in Internal Medicine, Gastroenterology and Transplant Hepatology

Interests: 
Hepatology, Viral Hepatitis, Endoscopic Procedures, Diagnostic Physiology Testing

 

Hepatology Research Projects:

Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1- A Phase 3 Safety and Efficacy Study.
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2b, ribavirin and boceprevir
Study subjects: Genotype 1 hepatitis C patients who have never been treated in the past.

A Phase 3, Safety and Efficacy Study of Boceprevir in Subjects with Chronic Hepatitis C Genotype 1 who failed prior treatment with peginterferon/ribavirin
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2b, ribavirin and boceprevir
Study subjects: Genotype 1 hepatitis C patients who have been treated in the past with pegylated interferon and ribavirin and achieved a partial response to therapy but failed to clear virus.

Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin.
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2a, ribavirin and boceprevir
Study subjects: Genotype 1 hepatitis C patients who have been treated in the past with pegylated interferon and ribavirin and achieved a partial response to therapy but failed to clear virus.

A Single-Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2b, ribavirin and boceprevir
Study subjects: Patients who were enrolled in other studies that included boceprevir therapy in one arm, were randomized to the study group who did not receive boceprevir therapy and failed to clear virus.

Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C.
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: None
Study subjects: Patients who were treated with boceprevir in any research study.

 

Selected Recent Publications

  1. Barnett C, Herrera JL. Sirolimus-associated interstitial pneumonitis in a liver transplant patient. Gastroenterology and Hepatology 2005; 1:70-73.

  2. Wilkes JM, Clark LE, Herrera JL. Acetaminophen overdose in pregnancy. South Med J 2005; 98:1118-1122.

  3. Barnett CB, Herrera JL, Black Esophagus. Practical Gastroenterology 2006; 30:54-55, 66.
  4. Herrera JL, Rodriquez R. Medical care of the patient with compensated cirrhosis. Gastroenterology and Hepatology 2006; 30:19-33.
  5. Herrera JL. Hepatobiliary complications of inflammatory bowel disease. Practical Gastroenterelogy 2006; 30:19-33.
  6. Clark LE, Herrera JL. Celiac Disease as a Cause of Abnormal Transaminases in Chronic Hepatitis B Infection. Practical Gastroenterol 2003;27:50-51,63.
  7. Tran LC, Woods AR, Herrera JL. Management of Hepatitis C Birus Infection. Drug Benefit Trends 2004; 16:266-276
  8. Woods AR, Herrera JL. Hepatitis C: Latest Treatment Guidelines. Consultant 2002; 42: 1233-1243.
  9. Smith JR, Herrera JL. Hepatitis C: Who should be treated? (Editorial) Practical Gastroenterology 2002; 26: 14-21.
  10. Adeniji O, Herrera JL. Finally: Changing the natural history of Hepatitis C! Am J Gastroenterol 2001 Nov; 96: 3200-1.
  11. Herrera JL. Liver Abscess. In: GI/Liver Secrets. P.R. McNally (ed). Philadelphia: Hanley and Belfus Inc. 2001:225-229.
  12. Yee LJ, Weiss HL, Langner RG, Herrera JL, Kaslow RA, van Leeuwen DJ. Risk factors for acquisition of hepatitis C infection. a case series and potential implications for disease surveillance. BMC Infectious Diseases 2001;1:8.
  13. Smith JR, Herrera JL. Antiviral therapy for hepatitis C infection. In: GI/Liver Secrets. P.R. McNally (ed). Philadelphia: Hanley and Belfus Inc 2001:107-112.
  14. Herrera JL, Smith JR. Antiviral therapy for hepatitis B. In: GI/Liver Secrets. P.R. McNally (ed) Philadelphia: Hanley and Belfus Inc. 2001:113-117.
  15. Smith JR, Herrera JL, Chronic Hepatitis C: Implications for the primary care clinician. JAAPA 2001; 14:41-44.
  16. Herrera JL. Confirming the diagnosis of hepatitis C virus infection. J Crit Illness 2000;15:350.
  17. Knott AW, Ampudia RJ, Evankovich C, Teplick S, Herrera JL, Tucker JA, Rodning CB.Biliary cystadenoma: Rare variant of intrahepatic cystic disease. south Med J 20000;93:698-702.
  18. Herrera JL. Guest Editor. Clinics in Liver Disease: Pathophysiology of Liver Disease. 4(2):May 2000. WB Saunders, Philadelphia.
  19. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich E, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. Assessment of hepatitis C virusRNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepatitis 2000;7:196-202.
  20. Herrera JL. The role of the primary care provider in diagnosing and managing chronic hepatitis C. The American Journal of Managed Care 2000;1(Sup 1):S22-S32.
  21. Herrera JL. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. Am J Gastroenterol 1999;94:3571-3575.
  22. Herrera JL. Chronic Hepatitis C: An overview. Am J Managed Care 1998;4 (Nov Supp):5691-5700.
  23. Herrera JL. Management of acute liver failure. Dig Dis 1998;16:274-283.
  24. Herrera JL, Roveda KP. Hepatitis C: What recent advances in therapy mean for your patients. Consultant 1999;32:436-447.
  25. Levy MJ, Herrera JL, DiPalma JA. Immune globuline and vaccine therapy to prevent hepatitis A infection. Am J Med 1998;105:416-423.
  26. Vollberg CM, Herrera JL. Vibro vulnificus infection: An important cause of septicemia in patients with cirrhosis. South Med J 1997; 90:1040-1042.
  27. Herrera JL. Hepatic medical injury. Curr Opinion Crit Care 1997;3:153-158.
  28. Maddrey WC, Greenberger NJ, Herrera JL, Koff RS, Schiff ER. Current Concepts in the diagnosis and management of hepatitis C. Clinical Courier 1996;14:1-38.
  29. Habeeb KS, Herrera JL. Management of ascites: Paracentesis as a guide. Post Grad Med 1997;101:191-200.
  30. Zuschke CA, Herrera JL, Pettyjohn FS. Cytomegalovirus hepatitis mimicking an acute exacerbation of chronic hepatitis F. Southern Med J 1996;89:1213-16.
  31. Herrera JL. Chronic viral hepatitis: Evaluation and treatment. Medico Interamericano 1995;11:489-92. (Spanish).
  32. Buckley SE, Herrera JL. Management of ascites. Comprehen Ther 1995;21:195-99.
  33. Herrera JL. Hepatobiliary abnormalities in the critically ill. Curr Opin Crit Care 1995;1:147-51.

 

Email Newsletters

Connect With Us